HemCheck has signed a long term agreement with SHL Technologies Limited, which is part of the international group SHL Group. The agreement means that SHL will produce the engångstester used in HemChecks product concepts Helge for point-of-care detection of hemolysis. HemChecks goal is to Helge, in 2018, the first to achieve the CE marking, as required, and then launched on the Swedish market.

– We are glad that we are able to sign a long-term agreement with SHL. SHL is a competent partner, both when it comes to dealing with large volumes and small batches, which is of great importance in the lanseringsskede that HemCheck soon go into, ” says managing director Annelie Brolinson in a comment.

– HemCheck has a unique product that will be able to contribute to the more efficient flow and large savings in the chain of care in Sweden and globally. We look forward to a continued and enhanced cooperation, ” says Gabor Papp, SHL Technologies.

– SHL has extensive global experience, something which in the next step can help us out in the world. In addition to this, SHL Group since the spring of 2017 one of the largest investors in the HemCheck AB That they have chosen to sign agreements with us shows that they believe in our mission and want to be an active business partner already from the early lanseringsskedet, continues Annelie Brolinson.

For further information, please contact:

Hemcheck Sweden AB (publ) Annelie Brolinson, managing director

Tel: +46 70 288 0826



If HemCheck

Hemcheck Sweden AB (publ) develops and commercializes a unique product concept, Helge, for point-of-care detection of hemolysis. Hemolysis, broken red blood cells, is the most common cause of blood samples can not be analyzed. This leads to worse care, the risks for the patients and high costs for society. HemChecks goal is to contribute to improved care for patients worldwide by developing and commercializing user-friendly products for the detection of hemolyzed blood samples in direct connection to the sampling. HemChecks the company is headquartered in Karlstad, Sweden.

If SHL Group

SHL Group develops and produces mainly products for injection and inhalation of drugs. With operations in Taiwan, China, Sweden and the united states is the SHL Group, the world’s largest supplier of autoinjektorer. Among their clients are the world’s largest pharmaceutical and biotech companies. SHL Group was formed in 1989 and has today a total of more than 3 700 employees.

Important information

This information is such information that hemCheck is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 11 January 2018, there is a 09.00

HemCheck SHL

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Hemcheck Sweden AB via Globenewswire

Leave a Reply